Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double posi… Read more
Phio Pharmaceuticals Corp - Asset Resilience Ratio
Phio Pharmaceuticals Corp (PHIO) has an Asset Resilience Ratio of 1.31% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how Phio Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Phio Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.00K | 1.31% |
| Total Liquid Assets | $50.00K | 1.31% |
Asset Resilience Insights
- Limited Liquidity: Phio Pharmaceuticals Corp maintains only 1.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Phio Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio
Compare Phio Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Phio Pharmaceuticals Corp (2012–2017)
The table below shows the annual Asset Resilience Ratio data for Phio Pharmaceuticals Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 1.22% | $50.00K | $4.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $13.40 Million | -- |
| 2015-12-31 | 49.29% | $5.50 Million | $11.16 Million | +48.74pp |
| 2014-12-31 | 0.54% | $50.00K | $9.19 Million | -19.54pp |
| 2013-12-31 | 20.08% | $3.00 Million | $14.94 Million | +19.14pp |
| 2012-12-31 | 0.95% | $53.00K | $5.59 Million | -- |